|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2021
|
|
gptkbp:atccode
|
L04 AA43
|
|
gptkbp:bioavailability
|
approximately 85%
|
|
gptkbp:casnumber
|
1252024-47-8
|
|
gptkbp:chemical_formula
|
C17 H20 N6 O2
|
|
gptkbp:class
|
gptkb:immunotherapy
anti-inflammatory
|
|
gptkbp:clinical_trial
|
Phase 3
NCT02820044
NCT03595666
NCT03675308
|
|
gptkbp:defines
|
gptkb:ABBV-181
|
|
gptkbp:developed_by
|
gptkb:Abb_Vie
|
|
gptkbp:effective_date
|
FDA approved
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Upadacitinib
|
|
gptkbp:indication
|
active psoriatic arthritis
moderate to severe ulcerative colitis
moderate to severe eczema
|
|
gptkbp:invention
|
patented
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
Janus kinase inhibitor
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
increased risk of infections
|
|
gptkbp:trade
|
gptkb:Rinvoq
|
|
gptkbp:used_for
|
gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis
atopic dermatitis
|
|
gptkbp:weight
|
328.38 g/mol
|
|
gptkbp:bfsParent
|
gptkb:EMD_Serono
|
|
gptkbp:bfsLayer
|
5
|